Trial data comparison: difference between revisions
Diff·revision 25 → 26·17:46, 8 Apr 2025
Difference between revision 25 and revision 26 of Trial data comparison. 3 lines changed; the page grew by 649 bytes.
| Revision 25 — 11:35, 3 Apr 2025 PrimarySrcPatia (talk) label community tally as self-reported 3,217 bytes ±0 | Revision 26 — 17:46, 8 Apr 2025 RfC_Rasmus (talk) rm unsourced claim per PP:V 3,866 bytes +649 | ||
|---|---|---|---|
| 31 | The '''trial-product estimand''' asks what happened while participants were taking the drug as intended. It answers "what does the molecule do", and it is the larger figure. | 31 | The '''trial-product estimand''' asks what happened while participants were taking the drug as intended. It answers "what does the molecule do", and it is the larger figure. |
| 32 | 32 | ||
| + | 33 | The gap between them is not small. In the STEP programme the two estimands for the same trial differed by roughly one to two percentage points of body weight, which is a difference of the same order as the gap between some of the drugs being compared.{{r|step1}} A table that mixes estimands between rows therefore manufactures apparent differences between compounds that are artefacts of the analysis choice. | |
| + | 34 | ||
| 33 | == References == | 35 | == References == |
| 34 | {{reflist}} | 36 | {{reflist}} |
| 35 | <ref name="ich9r1">International Council for Harmonisation, ''E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 37 | <ref name="ich9r1">International Council for Harmonisation, ''E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| + | 38 | <ref name="step1">Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> | |
| 36 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 39 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| 37 | 40 |